Company intelligence / Profile preview

Spring Bank Pharmaceuticals, Inc.

Milford, Massachusetts, United Statesannualreports.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Spring Bank was developing novel therapeutics using its proprietary SMNH platform. Its lead candidate SB 9200 showed antiviral activity against HCV-RNA by targeting host cytosolic sensor proteins. The company was also developing SB 11285, an IV-administered STING agonist for cancer treatment. Spring Bank was acquired by F-star Therapeutics in 2020.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Small molecule nucleic acid hybrids (SMNH)STING agonistsSTING antagonistsantibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

2 assets

inarigivir soproxil

Phase 2

Indications: Hepatitis B

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Spring Bank Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spring Bank Pharmaceuticals, Inc..

Explore the full profile